Venture capital investments in the biotechnology industry dropped 6% year-to-year to almost $1.3 billion during the fourth quarter of 2012, but the number of deals grew by 8% to 135 during the period, according to the quarterly MoneyTree Report. For the entire year, biotech firms secured almost $4.1 billion, a decline of 15% from 2011, while the number of deals was fairly steady at 466.

Related Summaries